Acute Antidepressant Effects of Intramuscular Versus Intravenous Ketamine
Open Access
- 1 January 2014
- journal article
- research article
- Published by SAGE Publications in Indian Journal of Psychological Medicine
- Vol. 36 (1), 71-76
- https://doi.org/10.4103/0253-7176.127258
Abstract
Objective: Conventional antidepressants take two weeks before their therapeutic action begins. Recent studies have reported on the rapid antidepressant effect of ketamine when given as an intravenous (I.V.) infusion. Little is known about its intramuscular (I.M.) use in depression. Hence this study was conducted to compare the safety, tolerability and efficacy of I.M. versus. I.V. ketamine in Major Depression (ICD-10). Materials and Methods: It was a randomized open label parallel group study in a tertiary care teaching hospital. Study sample consisted of 27 subjects having major depression divided randomly into three groups of nine subjects each. Ketamine administered to each group in the dose of 0.5 mg/kg as an I.V. infusion, as 0.5 mg/kg I.M. or 0.25 mg/kg I.M. respectively. Depression rated on the Hamilton Depression Rating Scale (HAM-D) before the injection, two hours later, the next day, and after three days. Data analyzed using the Statistical Package for Social Sciences (SPSS). Results: Mean age of the sample was 36.81 years (SD 11.815). Two hours after the injection, HAM-D fell by 58.86%, 60.29% & 57.36% in each group respectively. The improvement was sustained for next three days. Adverse effects noticed were rare, of mild nature and transient, lasting less than an hour. Conclusions: Intramuscular ketamine in the dose of 0.25 mg/kg is as effective and safe as 0.5 mg/kg given either I.M. or I.V., substantially alleviating depressive symptoms within a few hours and sustained for 3 days.Keywords
This publication has 19 references indexed in Scilit:
- Intramuscular ketamine in acute depression: A report on two casesIndian Journal of Psychiatry, 2013
- Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar–Kyoto ratsNeuroscience, 2012
- Rapid Antidepressant Response with Ketamine: Is it the Solution to Resistant Depression?Indian Journal of Psychological Medicine, 2012
- Topological Traps Control Flow on Real Networks: The Case of Coordination FailuresPLOS ONE, 2010
- Cracking the moody brain: Lifting the mood with ketamineNature Medicine, 2010
- Attention deficit hyperactivity disorder and sleep. Insomnia and other sleep problems may worsen symptoms of ADHD; treatment options exist.2010
- Brain-Derived Neurotrophic Factor and Initial Antidepressant Response to anN-Methyl-D-Aspartate AntagonistThe Journal of Clinical Psychiatry, 2009
- Chronic Administration of Ketamine Elicits Antidepressant‐Like Effects in Rats without Affecting Hippocampal Brain‐Derived Neurotrophic Factor Protein LevelsBasic & Clinical Pharmacology & Toxicology, 2008
- Intravenous ketamine therapy in a patient with a treatment-resistant major depressionSwiss Medical Weekly, 2007
- Antidepressant effects of ketamine in depressed patientsBiological Psychiatry, 2000